Ulticort Plus30 gm

Ulticort Plus is a fixed-dose combination of a super-potent topical corticosteroid (halobetasol propionate) and a topical retinoid (tazarotene), formulated as a lotion for dermatologic use.

FDA-Approved Indication

• Topical treatment of plaque psoriasis in adults (18 years and older).

Ulticort Plus is intended for short-term, localized application to affected skin areas only and is not indicated for widespread or long-term continuous use due to the potency of its corticosteroid component.

Each gram of Halobetasol Propionate + Tazarotene lotion typically contains halobetasol propionate 0.01% (super-potent Class I topical corticosteroid) and tazarotene 0.045% (topical retinoid), in a lotion base.

Ulticort Plus is a topical combination product developed to treat plaque psoriasis by pairing two agents with complementary mechanisms: a potent anti-inflammatory corticosteroid and a retinoid that normalizes epidermal cell growth. The combination is designed to improve efficacy while the corticosteroid component may help offset the local irritation commonly associated with retinoid monotherapy.

It is applied once daily as a thin layer to psoriatic plaques and is intended for use under medical supervision due to the potency of its ingredients.

Ulticort Plus belongs to the therapeutic class of topical antipsoriatic combination agents, combining a Class I (super-potent) topical corticosteroid with a topical retinoid.

Halobetasol Propionate + Tazarotene combines two agents with distinct mechanisms of action:

• Halobetasol propionate is a super-potent synthetic corticosteroid that binds intracellular glucocorticoid receptors, inducing anti-inflammatory, antipruritic, and vasoconstrictive proteins. This suppresses the inflammatory cascade characteristic of psoriatic plaques, reducing erythema, scaling, and plaque thickness.
• Tazarotene is a prodrug rapidly converted to its active form, tazarotenic acid, which binds retinoic acid receptors (RARs). This normalizes abnormal keratinocyte differentiation and proliferation and has anti-inflammatory effects, addressing the hyperproliferative epidermal changes seen in psoriasis.

Together, these mechanisms provide complementary anti-inflammatory and antiproliferative activity in the treatment of plaque psoriasis.

Ulticort Plus is for topical (external skin) use only. It is not for oral, ophthalmic, intravaginal, or mucosal use. Avoid contact with eyes, mouth, and mucous membranes. See Dosage and Administration for full application instructions.

Formal systemic drug-drug interaction studies have not been extensively conducted for Ulticort Plus due to its topical route of administration, but the following clinically relevant considerations apply:

• Other topical, oral, or injectable corticosteroids: Concurrent use may increase the risk of systemic corticosteroid effects and HPA-axis suppression; avoid combining with other potent corticosteroid products unless directed by a physician.
• Photosensitizing agents (e.g., certain antibiotics such as tetracyclines and fluoroquinolones, thiazide diuretics): May increase photosensitivity when combined with the tazarotene component; additional sun protection is advised.
• Other topical retinoids, keratolytics, or irritant products (e.g., products containing sulfur, resorcinol, salicylic acid, benzoyl peroxide): Concomitant use may increase local skin irritation.

The most commonly reported adverse reactions with Ulticort Plus include:

• Contact dermatitis
• Application site pain (burning, stinging)
• Folliculitis
• Skin atrophy
• Excoriation
• Pruritus (itching)
• Erythema at the application site

Less common but clinically important effects include striae, telangiectasia, and, with prolonged or extensive use, systemic corticosteroid effects such as HPA-axis suppression (see Precautions and Warnings).

Pregnancy: Ulticort Plus is contraindicated in pregnancy. The tazarotene component carries a risk of fetal harm based on data from other retinoids. Women of reproductive potential should have a negative pregnancy test within 2 weeks prior to starting therapy, should begin treatment during a menstrual period, and should use effective contraception during treatment. If pregnancy occurs during treatment, discontinue use immediately and consult a physician.

Lactation: It is not known whether topically applied Ulticort Plus is excreted in human milk in clinically significant amounts. Because many drugs are excreted in breast milk, use only if clearly needed and the potential benefit justifies the potential risk to the infant; avoid application to the chest/nipple area to prevent direct infant exposure, and consult a physician before use while breastfeeding.

The following precautions apply to the use of Ulticort Plus:

• Embryofetal risk: See Pregnancy and Lactation; effective contraception is required for patients of reproductive potential.
• HPA-axis suppression: As a super-potent corticosteroid combination, prolonged use, use over large body surface areas, or use under occlusion may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing syndrome, hyperglycemia, and glucosuria. Limit duration of treatment and total body surface area treated per physician instructions; total weekly dose should not exceed approximately 50 grams.
• Local irritation and photosensitivity: The tazarotene component may cause local irritation, burning, and increased photosensitivity. Minimize sun exposure, including sunlamps, and use sun protection measures during treatment.
• Site restrictions: Avoid application to the face, groin, axillae, and skin folds, and avoid use with occlusive dressings, unless specifically directed by a physician, due to increased risk of local and systemic adverse effects.
• Skin atrophy: Prolonged use of potent topical corticosteroids may cause skin atrophy, striae, and telangiectasia, particularly on thin-skinned areas.
• Ophthalmic effects: Avoid contact with eyes; retinoids and potent corticosteroids have been associated with increased risk of cataracts and glaucoma with periocular or prolonged use.
• Abrupt discontinuation: Avoid abruptly stopping treatment after prolonged use of the potent corticosteroid component, as this may unmask underlying disease or precipitate withdrawal effects; discontinuation should be guided by a physician.
• Concurrent skin infections: Not for use on skin with untreated bacterial, fungal, or viral infections at the application site, as corticosteroid use may mask or worsen infection.

Topical overdose or accidental ingestion of Ulticort Plus may result in significant systemic absorption of the corticosteroid component, potentially causing HPA-axis suppression, features of Cushing syndrome, hyperglycemia, or, with the retinoid component, mucocutaneous irritation. In case of accidental ingestion or signs of systemic toxicity, seek immediate medical attention or contact a poison control center; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light, moisture, and heat. Do not freeze. Keep out of reach of children.

Pediatric use: Safety and efficacy of Ulticort Plus in patients younger than 18 years have not been established; it is not approved for pediatric use.

Geriatric use: Clinical studies did not identify differences in response between elderly and younger patients; however, elderly patients may have thinner skin and could be at greater risk of local adverse effects such as skin atrophy. Use with appropriate monitoring.

Hepatic/renal impairment: No specific studies have been conducted; use with caution and physician guidance given potential for increased systemic corticosteroid absorption.

Pregnancy/lactation: See Pregnancy and Lactation section.

Treatment duration with Ulticort Plus should be limited to the shortest period necessary to achieve control of plaque psoriasis, as directed by a physician, due to the risk of HPA-axis suppression and local skin atrophy with prolonged use. Clinical trials have generally evaluated use for up to 8 weeks; use beyond the physician-recommended duration is not advised without reassessment.

Halobetasol Propionate + Tazarotene is classified as a topical corticosteroid-retinoid combination, combining a Class I super-potent corticosteroid with a topical retinoid, used in the antipsoriatic drug class.

Halobetasol Propionate + Tazarotene acts through two complementary mechanisms: the halobetasol propionate component binds glucocorticoid receptors to exert potent anti-inflammatory, antipruritic, and vasoconstrictive effects, while the tazarotene component is converted to tazarotenic acid, which binds retinoic acid receptors to normalize keratinocyte proliferation and differentiation. Together, these actions reduce plaque thickness, scaling, and inflammation in plaque psoriasis.

Ulticort Plus is not approved for use in patients younger than 18 years of age. Safety and efficacy in pediatric populations have not been established, and use in this age group is not recommended outside of physician-directed, closely monitored circumstances.